In today’s recent session, 0.84 million shares of the Abbott Laboratories (NYSE:ABT) have been traded, and its beta is 0.71. Most recently the company’s share price was $132.18, and it changed around -$1.18 or -0.89% from the last close, which brings the market valuation of the company to $229.96B. ABT at last check was trading at a discount to its 52-week high of $141.23, offering almost -6.85% off that amount. The share price’s 52-week low was $99.71, which indicates that the recent value has risen by an impressive 24.56% since then. We note from Abbott Laboratories’s average daily trading volume that its 10-day average is 6.66 million shares, with the 3-month average coming to 6.56 million.
Abbott Laboratories stock received a consensus recommendation rating of Buy, based on a mean score of 1.90. If we narrow it down even further, the data shows that 0 out of 30 analysts rate the stock as a Sell; another 7 rate it as Overweight. Among the rest, 10 recommended ABT as a Hold, whereas 12 deemed it a Buy, and 1 rated it as Underweight. Abbott Laboratories is expected to report earnings per share of 1.25 for the current quarter.
Abbott Laboratories (NYSE:ABT) trade information
Instantly ABT has been showing red trend so far today with a performance of -0.89% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 136.34 on recent trading dayincreased the stock’s daily price by 3.05%. The company’s shares are currently up 27.07% year-to-date, but still down -3.00% over the last five days. On the other hand, Abbott Laboratories (NYSE:ABT) is -1.05% down in the 30-day period. We can see from the shorts that 20.8 million shares have been sold at a short interest cover period of 3.54 day(s).
The consensus price target as assigned by Wall Street analysts is $140, which translates to bulls needing to increase their stock price by 5.59% from its current value. Analyst projections state that ABT is forecast to be at a low of $140 and a high of $140.
Abbott Laboratories (ABT) estimates and forecasts
The year-over-year growth rate is expected to be 6.40%, up from the previous year.
Consensus estimates provided by 22 financial analysts predict the company will bring in an average of 11.02B in revenue for the current quarter. 22 analysts expect Abbott Laboratories to make 11.35B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.38B and 10.63B respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 6.22%. Forecasts for the next quarter put sales growth at 6.75%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 29.98%. Abbott Laboratories earnings are expected to increase by 10.49% in 2025, but the outlook is positive 10.36% per year for the next five years.
ABT Dividends
Abbott Laboratories’s next quarterly earnings report is expected to be released on 2025-Apr-16. The annual dividend yield of the stock is 1.72 percent and its annual dividend per share was 2.28. It is important to note, however, that the 1.72% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision. The average dividend yield for the past five years averaged 1.67 per year.
Abbott Laboratories (NYSE:ABT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.54% of Abbott Laboratories shares, and 80.49% of them are in the hands of institutional investors. The stock currently has a share float of 80.93%. Abbott Laboratories stock is held by 3883.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.5932% of the shares, which is about 166.35 million shares worth $17.29 billion.
BLACKROCK INC., with 7.5619% or 131.13 million shares worth $13.63 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 54.8 shares worth $7.22 billion, making up 3.15% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard 500 Index Fund held roughly 48.19 shares worth around $6.35 billion, which represents about 2.77% of the total shares outstanding.
